Comments*

 
  • Therapeutics for Cognitive Aging

    Preserving Mental Vitality across the Lifespan

    Therapeutics for Cognitive Aging

    Preserving Mental Vitality across the Lifespan

    Organizer: Howard Fillit (Alzheimer's Drug Discovery Foundation)Presented by the Alzheimer's Drug Discovery Foundation and the New York Academy of Sciences
    Reported by Kathleen McGowan | Posted July 23, 2009

    Overview

    There is no consensus definition for cognitive aging, but the gradual decline in mental capacity across the human lifespan is neither subtle nor trivial. Beginning as early as age 20, the mental performance of normal healthy adults slowly deteriorates, as measured by a wide range of tests of memory, comprehension, cognitive function, and cognitive speed.

    On May 15, 2009, the New York Academy of Sciences, in cooperation with the Alzheimer's Drug Discovery Foundation, hosted a full-day conference exploring what researchers know about the neurobiology of cognitive aging, and how it may relate to other neurodegenerative disorders like Alzheimer's disease and dementia. Discussion also focused on how to define cognitive aging, whether it should be considered a treatable disease, and if so, what the goals of therapeutics should be. Researchers presented information about therapeutic targets and therapies in development, and considered regulatory challenges to bringing drugs for cognitive aging to market.

    Featured media


    Howard FillitOverview: Therapeutics for Cognitive Aging
    Howard Fillit (Alzheimer's Drug Discovery Foundation)

     

    Use the tabs above to find a meeting report and multimedia from this event. Speakers include:


    Timothy A. Salthouse (University of Virginia)
    Steven H. Ferris (New York University School of Medicine)
    Lenore J. Launer (National Institute on Aging)
    Patrick R. Hof (Mount Sinai School of Medicine)
    George Bartzokis (University of California, Los Angeles)
    Robin Kleiman (Pfizer Inc.)
    Victoria Luine (Hunter College, City University of New York)
    Jerry J. Buccafusco (Medical College of Georgia)
    Gary Small (University of California, Los Angeles)
    Paul S. Aisen (University of California, San Diego)
    Allan M. Green (attorney and expert on FDA regulation)


    Presented by

     

    EmailPrint